If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Prostate Cancer, Decision Resources is offering an exclusive analyst call entitled Avastin Fails to Significantly Improve Overall Survival in a Phase III Trial in Prostate Cancer: What are the Market Implications? Because this presentation will feature report updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. The recent news that the pivotal Phase III clinical trial for Roche/Genentech/Chugai’s Avastin failed to significantly improve overall survival in the first-line, metastatic, hormone-refractory setting will significantly impact the prostate cancer drug market. Avastin’s failure in prostate cancer casts substantial doubt over the potential of other angiogenesis inhibitors that are currently in clinical trials for metastatic prostate cancer. However, this recent development also offers an opportunity for other emerging therapies – most notably AstraZeneca’s zibotentan – to benefit, owing to reduced competition in combination with Sanofi-Aventis’s Taxotere and prednisone. This 15-minute analyst call, presented by Analyst Andrew Merron, Ph.D., will answer the following questions:
Dr. Merron will conduct a live Q & A session after the presentation. Registration Avastin Fails to Significantly Improve Overall Survival in a Phase III Trial in Prostate Cancer: What are the Market Implications? March 25, 2010 at 10 a.m. U.S. Eastern Time, 3 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Andrew Merron, Ph.D., is a research analyst in the oncology department at Decision Resources. Dr. Merron received his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses. Prior to obtaining his Ph.D., he earned his B.Sc. in biochemistry from the University of Bath. His degree included a one-year work placement at the Institute of Neurology in London.